COPD Clinical Trial
— RECOILOfficial title:
The Safety and Feasibility of Re-treating Patients With Severe Emphysema With the RePneu LVRC System: a Pilot Study.
Verified date | June 2017 |
Source | University Medical Center Groningen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Rationale:
The combined data from 3 studies outside the Unites States investigating the Lung Volume
Reduction Coil system (RePneu LVRC) showed statistically significant improvements in
pulmonary function, exercise capacity and quality of life at both 6-Months and 12-Months
post treatment. 24 months post treatment the improved pulmonary function and exercise
capacity are slightly decreasing. Retreating the patient with the LVR coil system in other
parts of the lung could potentially lead to new improvements in lung function, dyspnea,
exercise capacity and quality of life and may reduce the rate of decline.
Objective:
To investigate the safety and feasibility of re-treating patients with severe Chronic
Obstructive Pulmonary Disease (COPD) with the RePneu LVRC system.
Status | Completed |
Enrollment | 8 |
Est. completion date | September 2016 |
Est. primary completion date | September 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility |
Inclusion Criteria: 1. Treated with the RePneu LVRC system > 24 months ago. 2. Six months after the first bilateral treatment with the RePneu LVRC system the patient had a significant improvement above the established minimal important difference (MID) of 6-minute walk distance (6MWD: 26 meter) or of forced expiratory volume in 1 second (FEV1: 100ml) or of St. Georges Respiratory Questionnaire total score (SGRQ: 4 points). 3. Subject has marked dyspnea scoring =2 on mMRC scale of 0-4. 4. Subject has stopped smoking for at least 6 months prior to entering the study. 5. Subject read, understood and signed the Informed Consent form. 6. Subject has completed a pulmonary rehabilitation program within 6 months prior to treatment and/or regularly performing maintenance respiratory rehabilitation if initial supervised therapy occurred more than 6 months prior to baseline testing. 7. Subject has received Influenza vaccinations consistent with local recommendations and/or policy. Exclusion Criteria: 1. Subject has co-morbidities that may significantly reduce subject's ability to improve exercise capacity (e.g., severe arthritis, planned knee surgery) or baseline limitation on 6MWT is not due to dyspnea. 2. Subject has severe gas exchange abnormalities as defined by: PaCO2 >8.0 kPa; PaO2 < 6.0 kPa (room air). 3. Subject has a history of recurrent clinically significant respiratory infections, defined as 3 hospitalizations for respiratory infection during the year prior to enrollment. 4. Subject has severe pulmonary hypertension defined by right ventricular systolic pressure >50 mm Hg via echocardiogram. 5. Subject has an inability to walk >140 meters in 6 minutes. 6. Subject has evidence of other severe disease (such as, but not limited to, lung cancer or renal failure), which in the judgment of the investigator may compromise survival of the subject for the duration of the study. 7. Subject is pregnant or lactating, or plans to become pregnant within the study timeframe. 8. Subject has an inability to tolerate bronchoscopy under moderate sedation or general anesthesia. 9. Subject has clinically significant bronchiectasis. 10. Subject has giant bullae >1/3 lung volume. 11. Subject has had previous LVR surgery, lung transplantation or lobectomy. 12. Subject has been involved in pulmonary drug or device studies within 30 days prior to this study. 13. Subject is taking >20 mg prednisone (or equivalent dose of a similar steroid) daily. 14. Subject requires high level chronic immunomodulatory therapy to treat a moderate to severe chronic inflammatory autoimmune disorder. 15. Subject is on an antiplatelet (such as Plavix) or anticoagulant therapy (such as heparin or Coumadin) which cannot be stopped for 7 days prior to procedure. 16. Subject has a sensitivity or allergy to Nickel. 17. Subject has a known sensitivity to drugs required to perform bronchoscopy. 18. Subject has any other disease, condition(s) or habit(s) that would interfere with completion of study and follow up assessments, would increase risks of bronchoscopy or assessments, or in the judgment of the investigator would potentially interfere. |
Country | Name | City | State |
---|---|---|---|
Netherlands | University Medical Center Groningen | Groningen |
Lead Sponsor | Collaborator |
---|---|
University Medical Center Groningen |
Netherlands,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number and type of adverse effects as a measure of safety between baseline and 6 months follow up | The safety objective of this study is to identify the potential number and type of device-related and procedure-related adverse effects. | Baseline - 6 month follow up | |
Secondary | Change from Baseline in Lung function at 2 months | -Changes in FEV1 and FVC, 2 months following treatment | Baseline vs 2 month follow up | |
Secondary | Change from Baseline in Quality of life at 2 months | Change in the SGRQ score, 2 months following treatment Change in the CCQ score, 2 months following treatment |
Baseline vs 2 month follow up | |
Secondary | Change from Baseline in functional measures at 2 months | Change in the mMRC score, 2 months following treatment Change in the 6MWD, 2 months following treatment |
Baseline vs 2 month follow up | |
Secondary | Change from Baseline in Lung function at 6 months | Change in RV, 6 months following treatment Change in RV/TLC ratio, 6 months following treatment Changes in FEV1 and FVC, 6 months following treatment |
Baseline vs 6 month follow up | |
Secondary | Change from Baseline in quality of life at 6 months | Change in the SGRQ score, 6 months following treatment Change in the CCQ score, 6 months following treatment |
Baseline vs 6 month follow up | |
Secondary | Change from Baseline in functional measures at 6 months | Change in the mMRC score, 6 months following treatment Change in the 6MWD, 6 months following treatment |
Baseline vs 6 month follow up |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06000696 -
Healthy at Home Pilot
|
||
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04043728 -
Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study
|
N/A | |
Completed |
NCT04105075 -
COPD in Obese Patients
|
||
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Active, not recruiting |
NCT04075331 -
Mepolizumab for COPD Hospital Eosinophilic Admissions Pragmatic Trial
|
Phase 2/Phase 3 | |
Terminated |
NCT03640260 -
Respiratory Regulation With Biofeedback in COPD
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|
||
Withdrawn |
NCT04210050 -
Sleep Ventilation for Patients With Advanced Hypercapnic COPD
|
N/A | |
Terminated |
NCT03284203 -
Feasibility of At-Home Handheld Spirometry
|
N/A | |
Recruiting |
NCT06110403 -
Impact of Long-acting Bronchodilator- -Corticoid Inhaled Therapy on Ventilation, Lung Function and Breathlessness
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06040424 -
Comparison of Ipratropium / Levosalbutamol Fixed Dose Combination and Ipratropium and Levosalbutamol Free Dose Combination in pMDI Form in Stable Chronic Obstructive Pulmonary Disease (COPD) Patients
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Recruiting |
NCT04868357 -
Hypnosis for the Management of Anxiety and Breathlessness During a Pulmonary Rehabilitation Program
|
N/A | |
Completed |
NCT01892566 -
Using Mobile Health to Respond Early to Acute Exacerbations of COPD in HIV
|
N/A | |
Completed |
NCT04119856 -
Outgoing Lung Team - a Cross-sectorial Intervention in Patients With COPD
|
N/A | |
Completed |
NCT04485741 -
Strados System at Center of Excellence
|
||
Completed |
NCT03626519 -
Effects of Menthol on Dyspnoea in COPD Patients
|
N/A | |
Recruiting |
NCT04860375 -
Multidisciplinary Management of Severe COPD
|
N/A |